This opportunity is no longer accepting applications.
grant RFA-CA-24-006

Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)

The National Cancer Institute is offering funding to support research on developing a vaccine for Kaposi sarcoma herpesvirus (KSHV). The goal is to create a vaccine that can either prevent infection and diseases related to KSHV, like Kaposi sarcoma and multicentric Castleman disease, or treat those already infected. Research can include identifying targets for the vaccine, creating animal mode…

Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled Investigation of the Transmission of KSHV (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translat…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Cancer Institute

Dates

Opportunity Released: October 16, 2023
Open for Submission: October 16, 2023
Submission Deadline: December 4, 2024
Application Window Closes: December 4, 2024

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.